학술논문
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study
Document Type
Article
Author
Source
In: Cancer . (Cancer, 15 November 2021, 127(22):4198-4212)
Subject
Language
English
ISSN
10970142
0008543X
0008543X